Skip to main content
NCBI home page
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2011 Nov 7;6(6):933–945. doi: 10.2478/s11535-011-0076-y

Hepatitis C virus entry into the hepatocyte

Sandrine Belouzard 1,2,3,4, Laurence Cocquerel 1,2,3,4, Jean Dubuisson 1,2,3,4,✉
PMCID: PMC7089486  PMID: 32215118

Abstract

Hepatitis C virus (HCV) is a small enveloped virus with a positive stranded RNA genome belonging to the Flaviviridae family. The virion has the unique ability of forming a complex with lipoproteins, which is known as the lipoviroparticle. Lipoprotein components as well as the envelope proteins, E1 and E2, play a key role in virus entry into the hepatocyte. HCV entry is a complex multistep process involving sequential interactions with several cell surface proteins. The virus relies on glycosaminoglycans and possibly the low-density lipoprotein receptors to attach to cells. Furthermore, four specific entry factors are involved in the following steps which lead to virus internalization and fusion in early endosomes. These molecules are the scavenger receptor SRB1, tetraspanin CD81 and two tight junction proteins, Claudin-1 and Occludin. Although they are essential to HCV entry, the precise role of these molecules is not completely understood. Finally, hepatocytes are highly polarized cells and which likely affects the entry process. Our current knowledge on HCV entry is summarized in this review.

Keywords: Hepatitis C virus, Virus entry, Viral receptor, Membrane proteins

References

  • [1].Moradpour D., Penin F., Rice C.M. Replication of hepatitis C virus. Nat Rev Microbiol. 2007;5:453–463. doi: 10.1038/nrmicro1645. [DOI] [PubMed] [Google Scholar]
  • [2].Bartenschlager R., Penin F., Lohmann V., Andre P. Assembly of infectious hepatitis C virus particles. Trends Microbiol. 2011;19:95–103. doi: 10.1016/j.tim.2010.11.005. [DOI] [PubMed] [Google Scholar]
  • [3].Bartosch B., Cosset F.L. Studying HCV cell entry with HCV pseudoparticles (HCVpp) Methods Mol Biol. 2009;510:279–293. doi: 10.1007/978-1-59745-394-3_21. [DOI] [PubMed] [Google Scholar]
  • [4].Bartenschlager R. Hepatitis C virus molecular clones: from cDNA to infectious virus particles in cell culture. Curr Opin Microbiol. 2006;9:416–422. doi: 10.1016/j.mib.2006.06.012. [DOI] [PubMed] [Google Scholar]
  • [5].Bartosch B., Dubuisson J. Recent advances in hepatitis C virus entry. Viruses. 2010;2:692–709. doi: 10.3390/v2030692. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [6].Lavie M., Goffard A., Dubuisson J. Assembly of a functional HCV glycoprotein heterodimer. Curr Issues Mol Biol. 2007;9:71–86. [PubMed] [Google Scholar]
  • [7].Vieyres G., Thomas X., Descamps V., Duverlie G., Patel A.H., Dubuisson J. Characterization of the envelope glycoproteins associated with infectious hepatitis C virus. J Virol. 2010;84:10159–10168. doi: 10.1128/JVI.01180-10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [8].Pecheur E.I., Diaz O., Molle J., Icard V., Bonnafous P., Lambert O., et al. Morphological characterization and fusion properties of triglyceride-rich lipoproteins obtained from cells transduced with hepatitis C virus glycoproteins. J Biol Chem. 2010;285:25802–25811. doi: 10.1074/jbc.M110.131664. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [9].Kielian M., Rey F.A. Virus membrane-fusion proteins: more than one way to make a hairpin. Nat Rev Microbiol. 2006;4:67–76. doi: 10.1038/nrmicro1326. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [10].Albecka A., Montserret R., Krey T., Tarr A.W., Diesis E., Ball J.K., et al. Identification of new functional regions in hepatitis C virus envelope glycoprotein E2. J Virol. 2011;85:1777–1792. doi: 10.1128/JVI.02170-10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [11].Krey T., d’Alayer J., Kikuti C.M., Saulnier A., Damier-Piolle L., Petitpas I., et al. The disulfide bonds in glycoprotein E2 of hepatitis C virus reveal the tertiary organization of the molecule. PLoS Pathog. 2010;6:e1000762. doi: 10.1371/journal.ppat.1000762. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [12].Drummer H.E., Poumbourios P. Hepatitis C virus glycoprotein E2 contains a membrane-proximal heptad repeat sequence that is essential for E1E2 glycoprotein heterodimerization and viral entry. J Biol Chem. 2004;279:30066–30072. doi: 10.1074/jbc.M405098200. [DOI] [PubMed] [Google Scholar]
  • [13].Scarselli E., Ansuini H., Cerino R., Roccasecca R.M., Acali S., Filocamo G., et al. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J. 2002;21:5017–5025. doi: 10.1093/emboj/cdf529. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [14].Prentoe J., Jensen T.B., Meuleman P., Serre S.B., Scheel T.K., Leroux-Roels G., et al. Hypervariable region 1 differentially impacts viability of hepatitis C virus strains of genotypes 1 to 6 and impairs virus neutralization. J Virol. 2011;85:2224–2234. doi: 10.1128/JVI.01594-10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [15].Bankwitz D., Steinmann E., Bitzegeio J., Ciesek S., Friesland M., Herrmann E., et al. Hepatitis C virus hypervariable region 1 modulates receptor interactions, conceals the CD81 binding site, and protects conserved neutralizing epitopes. J Virol. 2010;84:5751–5763. doi: 10.1128/JVI.02200-09. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [16].Helle F., Goffard A., Morel V., Duverlie G., McKeating J., Keck Z.Y., et al. The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein. J Virol. 2007;81:8101–8111. doi: 10.1128/JVI.00127-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [17].McCaffrey K., Gouklani H., Boo I., Poumbourios P., Drummer H.E. The variable regions of hepatitis C virus glycoprotein E2 have an essential structural role in glycoprotein assembly and virion infectivity. J Gen Virol. 2011;92:112–121. doi: 10.1099/vir.0.026385-0. [DOI] [PubMed] [Google Scholar]
  • [18].Helle F., Vieyres G., Elkrief L., Popescu C.I., Wychowski C., Descamps V., et al. Role of N-linked glycans in the functions of hepatitis C virus envelope proteins incorporated into infectious virions. J Virol. 2010;84:11905–11915. doi: 10.1128/JVI.01548-10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [19].Andre P., Perlemuter G., Budkowska A., Brechot C., Lotteau V. Hepatitis C virus particles and lipoprotein metabolism. Semin Liver Dis. 2005;25:93–104. doi: 10.1055/s-2005-864785. [DOI] [PubMed] [Google Scholar]
  • [20].Merz A., Long G., Hiet M.S., Brugger B., Chlanda P., Andre P., et al. Biochemical and morphological properties of hepatitis C virus particles and determination of their lipidome. J Biol Chem. 2011;286:3018–3032. doi: 10.1074/jbc.M110.175018. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [21].Andreo U., Maillard P., Kalinina O., Walic M., Meurs E., Martinot M., et al. Lipoprotein lipase mediates hepatitis C virus (HCV) cell entry and inhibits HCV infection. Cell Microbiol. 2007;9:2445–2456. doi: 10.1111/j.1462-5822.2007.00972.x. [DOI] [PubMed] [Google Scholar]
  • [22].Shimizu Y., Hishiki T., Sugiyama K., Ogawa K., Funami K., Kato A., et al. Lipoprotein lipase and hepatic triglyceride lipase reduce the infectivity of hepatitis C virus (HCV) through their catalytic activities on HCV-associated lipoproteins. Virology. 2010;407:152–159. doi: 10.1016/j.virol.2010.08.011. [DOI] [PubMed] [Google Scholar]
  • [23].Chang K.S., Jiang J., Cai Z., Luo G. Human apolipoprotein e is required for infectivity and production of hepatitis C virus in cell culture. J Virol. 2007;81:13783–13793. doi: 10.1128/JVI.01091-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [24].Hishiki T., Shimizu Y., Tobita R., Sugiyama K., Ogawa K., Funami K., et al. Infectivity of hepatitis C virus is influenced by association with apolipoprotein E isoforms. J Virol. 2010;84:12048–12057. doi: 10.1128/JVI.01063-10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [25].Meunier J.C., Russell R.S., Engle R.E., Faulk K.N., Purcell R.H., Emerson S.U. Apolipoprotein c1 association with hepatitis C virus. J Virol. 2008;82:9647–9656. doi: 10.1128/JVI.00914-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [26].Dubuisson J., Helle F., Cocquerel L. Early steps of the hepatitis C virus life cycle. Cell Microbiol. 2008;10:821–827. doi: 10.1111/j.1462-5822.2007.01107.x. [DOI] [PubMed] [Google Scholar]
  • [27].Helle F., Dubuisson J. Hepatitis C virus entry into host cells. Cell Mol Life Sci. 2008;65:100–112. doi: 10.1007/s00018-007-7291-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [28].Catanese M.T., Ansuini H., Graziani R., Huby T., Moreau M., Ball J.K., et al. Role of scavenger receptor class B type I in hepatitis C virus entry: kinetics and molecular determinants. J Virol. 2010;84:34–43. doi: 10.1128/JVI.02199-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [29].Dreux M., Dao Thi V.L., Fresquet J., Guerin M., Julia Z., Verney G., et al. Receptor complementation and mutagenesis reveal SR-BI as an essential HCV entry factor and functionally imply its intra- and extra-cellular domains. PLoS Pathog. 2009;5:e1000310. doi: 10.1371/journal.ppat.1000310. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [30].Eyre N.S., Drummer H.E., Beard M.R. The SR-BI partner PDZK1 facilitates hepatitis C virus entry. PLoS Pathog. 2010;6:e1001130. doi: 10.1371/journal.ppat.1001130. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [31].Zeisel M.B., Koutsoudakis G., Schnober E.K., Haberstroh A., Blum H.E., Cosset F.L., et al. Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81. Hepatology. 2007;46:1722–1731. doi: 10.1002/hep.21994. [DOI] [PubMed] [Google Scholar]
  • [32].Maillard P., Huby T., Andreo U., Moreau M., Chapman J., Budkowska A. The interaction of natural hepatitis C virus with human scavenger receptor SR-BI/Cla1 is mediated by ApoB-containing lipoproteins. FASEB J. 2006;20:735–737. doi: 10.1096/fj.05-4728fje. [DOI] [PubMed] [Google Scholar]
  • [33].Dorner M., Horwitz J.A., Robbins J.B., Barry W.T., Feng Q., Mu K., et al. A genetically humanized mouse model for hepatitis C virus infection. Nature. 2011;474:208–211. doi: 10.1038/nature10168. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [34].Pileri P., Uematsu Y., Campagnoli S., Galli G., Falugi F., Petracca R., et al. Binding of hepatitis C virus to CD81. Science. 1998;282:938–941. doi: 10.1126/science.282.5390.938. [DOI] [PubMed] [Google Scholar]
  • [35].Zhang J., Randall G., Higginbottom A., Monk P., Rice C.M., McKeating J.A. CD81 is required for hepatitis C virus glycoprotein-mediated viral infection. J Virol. 2004;78:1448–1455. doi: 10.1128/JVI.78.3.1448-1455.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [36].Kitadokoro K., Bordo D., Galli G., Petracca R., Falugi F., Abrignani S., et al. CD81 extracellular domain 3D structure: insight into the tetraspanin superfamily structural motifs. EMBO J. 2001;20:12–18. doi: 10.1093/emboj/20.1.12. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [37].Akazawa D., Date T., Morikawa K., Murayama A., Miyamoto M., Kaga M., et al. CD81 expression is important for the permissiveness of Huh7 cell clones for heterogeneous hepatitis C virus infection. J Virol. 2007;81:5036–5045. doi: 10.1128/JVI.01573-06. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [38].Koutsoudakis G., Herrmann E., Kallis S., Bartenschlager R., Pietschmann T. The level of CD81 cell surface expression is a key determinant for productive entry of hepatitis C virus into host cells. J Virol. 2007;81:588–598. doi: 10.1128/JVI.01534-06. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [39].Roohvand F., Maillard P., Lavergne J.P., Boulant S., Walic M., Andreo U., et al. Initiation of hepatitis C virus infection requires the dynamic microtubule network: role of the viral nucleocapsid protein. J Biol Chem. 2009;284:13778–13791. doi: 10.1074/jbc.M807873200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [40].Rocha-Perugini V., Lavie M., Delgrange D., Canton J., Pillez A., Potel J., et al. The association of CD81 with tetraspanin-enriched microdomains is not essential for Hepatitis C virus entry. BMC Microbiol. 2009;9:111. doi: 10.1186/1471-2180-9-111. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [41].Silvie O., Charrin S., Billard M., Franetich J.F., Clark K.L., van Gemert G.J., et al. Cholesterol contributes to the organization of tetraspaninenriched microdomains and to CD81-dependent infection by malaria sporozoites. J Cell Sci. 2006;119:1992–2002. doi: 10.1242/jcs.02911. [DOI] [PubMed] [Google Scholar]
  • [42].Rocha-Perugini V., Montpellier C., Delgrange D., Wychowski C., Helle F., Pillez A., et al. The CD81 partner EWI-2wint inhibits hepatitis C virus entry. PLoS ONE. 2008;3:e1866. doi: 10.1371/journal.pone.0001866. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [43].Montpellier C., Tews B.A., Poitrimole J., Rocha-Perugini V., D’Arienzo V., Potel J., et al. Interacting regions of CD81 and two of its partners, EWI-2 and EWI-2wint and their effect on Hepatitis C Virus infection. J Biol Chem. 2011;286:13954–13965. doi: 10.1074/jbc.M111.220103. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [44].Tsukita S., Furuse M., Itoh M. Multifunctional strands in tight junctions. Nat Rev Mol Cell Biol. 2001;2:285–293. doi: 10.1038/35067088. [DOI] [PubMed] [Google Scholar]
  • [45].Furuse M. Molecular basis of the core structure of tight junctions. Cold Spring Harb Perspect Biol. 2010;2:a002907. doi: 10.1101/cshperspect.a002907. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [46].Evans M.J., von Hahn T., Tscherne D.M., Syder A.J., Panis M., Wolk B., et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature. 2007;446:801–805. doi: 10.1038/nature05654. [DOI] [PubMed] [Google Scholar]
  • [47].Ploss A., Evans M.J., Gaysinskaya V.A., Panis M., You H., de Jong Y.P., et al. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature. 2009;457:882–886. doi: 10.1038/nature07684. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [48].Fofana I., Krieger S.E., Grunert F., Glauben S., Xiao F., Fafi-Kremer S., et al. Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes. Gastroenterology. 2010;139:953–964. doi: 10.1053/j.gastro.2010.05.073. [DOI] [PubMed] [Google Scholar]
  • [49].Zheng A., Yuan F., Li Y., Zhu F., Hou P., Li J., et al. Claudin-6 and claudin-9 function as additional coreceptors for hepatitis C virus. J Virol. 2007;81:12465–12471. doi: 10.1128/JVI.01457-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [50].Meertens L., Bertaux C., Cukierman L., Cormier E., Lavillette D., Cosset F.L., et al. The tight junction proteins claudin-1, -6, and -9 are entry cofactors for hepatitis C virus. J Virol. 2008;82:3555–3560. doi: 10.1128/JVI.01977-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [51].Cukierman L., Meertens L., Bertaux C., Kajumo F., Dragic T. Residues in a highly conserved claudin-1 motif are required for hepatitis C virus entry and mediate the formation of cell-cell contacts. J Virol. 2009;83:5477–5484. doi: 10.1128/JVI.02262-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [52].Haid S., Windisch M.P., Bartenschlager R., Pietschmann T. Mouse-specific residues of claudin-1 limit hepatitis C virus genotype 2a infection in a human hepatocyte cell line. J Virol. 2010;84:964–975. doi: 10.1128/JVI.01504-09. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [53].Benedicto I., Molina-Jimenez F., Bartosch B., Cosset F.L., Lavillette D., Prieto J., et al. The tight junction-associated protein occludin is required for a postbinding step in hepatitis C virus entry and infection. J Virol. 2009;83:8012–8020. doi: 10.1128/JVI.00038-09. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [54].Liu S., Yang W., Shen L., Turner J.R., Coyne C.B., Wang T. Tight junction proteins claudin-1 and occludin control hepatitis C virus entry and are downregulated during infection to prevent superinfection. J Virol. 2009;83:2011–2014. doi: 10.1128/JVI.01888-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [55].Michta M.L., Hopcraft S.E., Narbus C.M., Kratovac Z., Israelow B., Sourisseau M., et al. Species-specific regions of occludin required by hepatitis C virus for cell entry. J Virol. 2010;84:11696–11708. doi: 10.1128/JVI.01555-10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [56].Ciesek S., Steinmann E., Iken M., Ott M., Helfritz F.A., Wappler I., et al. Glucocorticosteroids increase cell entry by hepatitis C virus. Gastroenterology. 2010;138:1875–1884. doi: 10.1053/j.gastro.2010.02.004. [DOI] [PubMed] [Google Scholar]
  • [57].Benedicto I., Molina-Jimenez F., Barreiro O., Maldonado-Rodriguez A., Prieto J., Moreno-Otero R., et al. Hepatitis C virus envelope components alter localization of hepatocyte tight junction-associated proteins and promote occludin retention in the endoplasmic reticulum. Hepatology. 2008;48:1044–1053. doi: 10.1002/hep.22465. [DOI] [PubMed] [Google Scholar]
  • [58].Zeisel M.B., Fofana I., Fafi-Kremer S., Baumert T.F. Hepatitis C virus entry into hepatocytes: Molecular mechanisms and targets for antiviral therapies. J Hepatol. 2011;54:566–576. doi: 10.1016/j.jhep.2010.10.014. [DOI] [PubMed] [Google Scholar]
  • [59].Molina S., Castet V., Fournier-Wirth C., Pichard-Garcia L., Avner R., Harats D., et al. The low-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virus. J Hepatol. 2007;46:411–419. doi: 10.1016/j.jhep.2006.09.024. [DOI] [PubMed] [Google Scholar]
  • [60].Owen D.M., Huang H., Ye J., Gale M., Jr. Apolipoprotein E on hepatitis C virion facilitates infection through interaction with low-density lipoprotein receptor. Virology. 2009;394:99–108. doi: 10.1016/j.virol.2009.08.037. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [61].Harris H.J., Farquhar M.J., Mee C.J., Davis C., Reynolds G.M., Jennings A., et al. CD81 and claudin 1 coreceptor association: role in hepatitis C virus entry. J Virol. 2008;82:5007–5020. doi: 10.1128/JVI.02286-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [62].Harris H.J., Davis C., Mullins J.G., Hu K., Goodall M., Farquhar M.J., et al. Claudin association with CD81 defines hepatitis C virus entry. J Biol Chem. 2010;285:21092–21102. doi: 10.1074/jbc.M110.104836. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [63].Krieger S.E., Zeisel M.B., Davis C., Thumann C., Harris H.J., Schnober E.K., et al. Inhibition of hepatitis C virus infection by anti-claudin-1 antibodies is mediated by neutralization of E2-CD81-claudin-1 associations. Hepatology. 2010;51:1144–1157. doi: 10.1002/hep.23445. [DOI] [PubMed] [Google Scholar]
  • [64].Lupberger J., Zeisel M.B., Xiao F., Thumann C., Fofana I., Zona L., et al. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med. 2011;17:589–595. doi: 10.1038/nm.2341. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [65].Coller K.E., Berger K.L., Heaton N.S., Cooper J.D., Yoon R., Randall G. RNA interference and single particle tracking analysis of hepatitis C virus endocytosis. PLoS Pathog. 2009;5:e1000702. doi: 10.1371/journal.ppat.1000702. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [66].Brazzoli M., Bianchi A., Filippini S., Weiner A., Zhu Q., Pizza M., et al. CD81 is a central regulator of cellular events required for hepatitis C virus infection of human hepatocytes. J Virol. 2008;82:8316–8329. doi: 10.1128/JVI.00665-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [67].Blanchard E., Belouzard S., Goueslain L., Wakita T., Dubuisson J., Wychowski C., et al. Hepatitis C virus entry depends on clathrin-mediated endocytosis. J Virol. 2006;80:6964–6972. doi: 10.1128/JVI.00024-06. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [68].Meertens L., Bertaux C., Dragic T. Hepatitis C virus entry requires a critical postinternalization step and delivery to early endosomes via clathrin-coated vesicles. J Virol. 2006;80:11571–11578. doi: 10.1128/JVI.01717-06. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [69].Veiga E., Cossart P. Listeria hijacks the clathrin-dependent endocytic machinery to invade mammalian cells. Nat Cell Biol. 2005;7:894–900. doi: 10.1038/ncb1292. [DOI] [PubMed] [Google Scholar]
  • [70].Reynolds G.M., Harris H.J., Jennings A., Hu K., Grove J., Lalor P.F., et al. Hepatitis C virus receptor expression in normal and diseased liver tissue. Hepatology. 2008;47:418–427. doi: 10.1002/hep.22028. [DOI] [PubMed] [Google Scholar]
  • [71].Mee C.J., Harris H.J., Farquhar M.J., Wilson G., Reynolds G., Davis C., et al. Polarization restricts hepatitis C virus entry into HepG2 hepatoma cells. J Virol. 2009;83:6211–6221. doi: 10.1128/JVI.00246-09. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [72].Schwarz A.K., Grove J., Hu K., Mee C.J., Balfe P., McKeating J.A. Hepatoma cell density promotes claudin-1 and scavenger receptor BI expression and hepatitis C virus internalization. J Virol. 2009;83:12407–12414. doi: 10.1128/JVI.01552-09. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [73].Mee C.J., Grove J., Harris H.J., Hu K., Balfe P., McKeating J.A. Effect of cell polarization on hepatitis C virus entry. J Virol. 2008;82:461–470. doi: 10.1128/JVI.01894-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [74].Timpe J.M., Stamataki Z., Jennings A., Hu K., Farquhar M.J., Harris H.J., et al. Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies. Hepatology. 2008;47:17–24. doi: 10.1002/hep.21959. [DOI] [PubMed] [Google Scholar]
  • [75].Witteveldt J., Evans M.J., Bitzegeio J., Koutsoudakis G., Owsianka A.M., Angus A.G., et al. CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells. J Gen Virol. 2009;90:48–58. doi: 10.1099/vir.0.006700-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [76].Jones C.T., Catanese M.T., Law L.M., Khetani S.R., Syder A.J., Ploss A., et al. Real-time imaging of hepatitis C virus infection using a fluorescent cell-based reporter system. Nat Biotechnol. 2010;28:167–171. doi: 10.1038/nbt.1604. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [77].Brimacombe C.L., Grove J., Meredith L.W., Hu K., Syder A.J., Flores M.V., et al. Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission. J Virol. 2011;85:596–605. doi: 10.1128/JVI.01592-10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [78].Meuleman P., Hesselgesser J., Paulson M., Vanwolleghem T., Desombere I., Reiser H., et al. Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo. Hepatology. 2008;48:1761–1768. doi: 10.1002/hep.22547. [DOI] [PubMed] [Google Scholar]
  • [79].Russell R.S., Meunier J.C., Takikawa S., Faulk K., Engle R.E., Bukh J., et al. Advantages of a single-cycle production assay to study cell culture-adaptive mutations of hepatitis C virus. Proc Natl Acad Sci U S A. 2008;105:4370–4375. doi: 10.1073/pnas.0800422105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [80].Haid S., Pietschmann T., Pecheur E.I. Low pH-dependent hepatitis C virus membrane fusion depends on E2 integrity, target lipid composition, and density of virus particles. J Biol Chem. 2009;284:17657–17667. doi: 10.1074/jbc.M109.014647. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [81].Abell B.A., Brown D.T. Sindbis virus membrane fusion is mediated by reduction of glycoprotein disulfide bridges at the cell surface. J Virol. 1993;67:5496–5501. doi: 10.1128/jvi.67.9.5496-5501.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [82].Fenouillet E., Barbouche R., Jones I.M. Cell entry by enveloped viruses: redox considerations for HIV and SARS-coronavirus. Antioxid Redox Signal. 2007;9:1009–1034. doi: 10.1089/ars.2007.1639. [DOI] [PubMed] [Google Scholar]

Articles from Central European Journal of Biology are provided here courtesy of Nature Publishing Group

RESOURCES